Most material SEC filings — October 21, 2026

The U.S. Department of Transportation announced a $249 million federal grant (80% of $311M total project cost) to complete the Port MacKenzie Rail Extension in Alaska. The 32-mile rail line will connect Port MacKenzie to Alaska Railroad's main line and include a direct rail siding at Nova Minerals' planned antimony processing and refining facility, enabling ore and concentrate shipments from Alaska's interior. State and local partners will contribute the remaining $62 million; construction expected to begin spring 2027.

Vivos Therapeutics received Nasdaq confirmation on October 20, 2026, that it meets the minimum $2.5M stockholders' equity listing requirement. This compliance follows closure of an acquisition of 11% equity in SOD Sciences and 50% co-ownership of SOD's pseudohypoxia diagnostic test, funded by issuance of 12,000 shares of Series C Convertible Preferred Stock with $12M stated value. The preferred stock, convertible at $0.15/share into up to 80M common shares (subject to 19.99% cap and 4.99% ownership limits pending shareholder approval), is expected to increase stockholders' equity by >$10M.

Roivant/Priovant announced positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib 45 mg in non-infectious uveitis (NIU): met primary endpoint (time to treatment failure; hazard ratios 0.27 and 0.22 vs. placebo; p<0.0001 both studies) and all key secondary endpoints. Pooled data: 62% vs. 20% achieved steroid-free quiescence at Week 48 (p<0.0001); median time to failure >48 weeks vs. ~12 weeks on placebo. Priovant plans supplemental NDA filing in H1 2027. Safety profile consistent with prior trials; no new signals. No specific financial figures disclosed.

Healthcare Services Group completed the acquisition of NEXDINE Hospitality on October 6, 2026, for $93.5 million in cash, expected to contribute over $150 million in annual revenue at comparable margins and be immediately accretive to earnings. The company raised its 2027 revenue growth outlook from mid single-digits to low double-digits. Q3 2026 revenue was $479.6 million with net income of $24.9 million ($0.36 diluted EPS); the company also recorded a $6.1 million recovery from the Genesis bankruptcy case and repurchased $11.7 million of stock during the quarter.

Wabtec (NYSE: WAB) reported Q3 2026 sales of $3.12B (+8.1% YoY), GAAP diluted EPS of $2.42 (+33.7% YoY), and adjusted diluted EPS of $2.83 (+22.0% YoY). The company raised and tightened full-year 2026 adjusted EPS guidance by $0.20 at the midpoint to $10.85–$11.05 (up 22% vs. 2025), driven by strong operational performance, margin expansion (adjusted operating margin +1.9 pts to 22.9%), and contributions from acquisitions (Frauscher Sensor Technologies, Dellner Couplers). Total backlog reached $31.4B (+22.9% YoY), with 12-month backlog at $9.0B (+8.8% YoY). The company returned $920M to shareholders YTD through $855M in share repurchases and $65M in dividends.